Cargando…

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial

BACKGROUND: Cisplatin and gemcitabine is the standard first-line chemotherapy regimen for patients with advanced biliary tract cancer; expression of VEGF and its receptors is associated with adverse outcomes. We aimed to assess the effect of the addition of cediranib (an oral inhibitor of VEGF recep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valle, Juan W, Wasan, Harpreet, Lopes, Andre, Backen, Alison C, Palmer, Daniel H, Morris, Karen, Duggan, Marian, Cunningham, David, Anthoney, D Alan, Corrie, Pippa, Madhusudan, Srinivasan, Maraveyas, Anthony, Ross, Paul J, Waters, Justin S, Steward, Will P, Rees, Charlotte, Beare, Sandy, Dive, Caroline, Bridgewater, John A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lancet Pub. Group 2015
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648082/ https://www.ncbi.nlm.nih.gov/pubmed/26179201 http://dx.doi.org/10.1016/S1470-2045(15)00139-4

Ejemplares similares

Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial
por: Backen, Alison C., et al.
Publicado: (2018)

Quality of life, long-term survivors and long-term outcome from the ABC-02 study
por: Bridgewater, John, et al.
Publicado: (2016)

A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study
por: Bridgewater, John, et al.
Publicado: (2016)

Erratum to: A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study
por: Bridgewater, John, et al.
Publicado: (2016)

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study
por: Valle, J W, et al.
Publicado: (2009)

PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer
por: Pereira, Stephen P, et al.
Publicado: (2018)

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
por: Lamarca, Angela, et al.
Publicado: (2021)

Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer
por: Gopinathan, Ganga, et al.
Publicado: (2022)

Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma
por: Brown, Nicholas, et al.
Publicado: (2016)

Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers
por: Zhou, C., et al.
Publicado: (2022)

Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials
por: McNamara, Mairéad Geraldine, et al.
Publicado: (2017)

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
por: Corrie, P. G., et al.
Publicado: (2020)

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma
por: Nguyen, James, et al.
Publicado: (2023)

Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy
por: Spencer, S K M, et al.
Publicado: (2013)

Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma
por: Lobo, Merryl R., et al.
Publicado: (2015)

Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial
por: Symonds, R Paul, et al.
Publicado: (2015)

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial
por: Mukherjee, Somnath, et al.
Publicado: (2013)

Combined Efficacy of Cediranib and Quinacrine in Glioma Is Enhanced by Hypoxia and Causally Linked to Autophagic Vacuole Accumulation
por: Lobo, Merryl R., et al.
Publicado: (2014)

Identification of target genes of cediranib in alveolar soft part sarcoma using a gene microarray
por: Jiang, Wenhua, et al.
Publicado: (2017)

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
por: Bekaii-Saab, Tanios S, et al.
Publicado: (2020)

Gemcitabine Conjugated Chitosan and Double Antibodies (Abc-GC-Gemcitabine Nanoparticles) Enhanced Cytoplasmic Uptake of Gemcitabine and Inhibit Proliferation and Metastasis In Human SW1990 Pancreatic Cancer Cells
por: Xiao, Jun, et al.
Publicado: (2017)

Long-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/Lomustine
por: Drazin, Doniel, et al.
Publicado: (2016)

Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial
por: Stark, Dan P., et al.
Publicado: (2017)

Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy
por: Bi, Jianling, et al.
Publicado: (2021)

Combination studies with gemcitabine in the treatment of non-small-cell lung cancer.
por: Steward, W. P.
Publicado: (1998)

Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
por: Kim, Joseph W., et al.
Publicado: (2021)

Une urgence médico-chirurgicale rare: l’abcès épidural rachidien (à propos de 03 cas)
por: Saqui, Abderrazzak El, et al.
Publicado: (2017)

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
por: Jürgensmeier, J M, et al.
Publicado: (2013)

Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab
por: Suffredini, Dante A., et al.
Publicado: (2018)

Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer
por: Lin, Z. Ping, et al.
Publicado: (2018)

Vitamin D Enhances Anticancer Properties of Cediranib, a VEGFR Inhibitor, by Modulation of VEGFR2 Expression in Melanoma Cells
por: Piotrowska, Anna, et al.
Publicado: (2021)

Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study
por: Maraveyas, A, et al.
Publicado: (2005)

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer
por: Raja, F A, et al.
Publicado: (2011)

Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture
por: Jiang, Yanyan, et al.
Publicado: (2015)

A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503)
por: Sahebjam, S, et al.
Publicado: (2013)

Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial
por: Judson, Ian, et al.
Publicado: (2019)

Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
por: Kim, Joseph W., et al.
Publicado: (2023)

Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs
por: Brookes, K, et al.
Publicado: (2010)

CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone
por: Wasan, H S, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_15t3pqogsknh2voqmlbitogp86